Abstract
Editorial summaryGenomic medicine has considerable potential to provide novel diagnostic and therapeutic solutions for patients who have molecularly complex diseases and who are not responding to existing therapies. To bridge the gap between genomic medicine and clinical practice, integration of various data types, resources, and joint international initiatives will be required.
Highlights
Genomic medicine has considerable potential to provide novel diagnostic and therapeutic solutions for patients who have molecularly complex diseases and who are not responding to existing therapies
Promise and pitfalls of genomic medicine, focusing on genetic alterations An early, successful example of a drug that targets somatic genetic alterations was imatinib, a tyrosine kinase inhibitor that is used for the treatment of chronic myeloid leukemia patients who have a translocation that results in the formation of a constitutively active BCR-ABL fusion kinase [2]
(2019) 11:9 epidermal growth factor receptor (EGFR) with EGFR inhibitors, and the treatment of melanomas bearing mutated BRAF with BRAF inhibitors [2]. These successful examples have spurred concerted efforts to generalize genomic approaches to the treatment of disease, including those based at the National Cancer Institute (NCI), the National Institutes of Health (NIH), and several European and Asian centers
Summary
Genomic medicine has considerable potential to provide novel diagnostic and therapeutic solutions for patients who have molecularly complex diseases and who are not responding to existing therapies. To bridge the gap between genomic medicine and clinical practice, integration of various data types, resources, and joint international initiatives will be required.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.